Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when BTMD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CEO (new) — The CEO resigned from his position, triggering a leadership transition with an interim replacement.
Biote CEO Bret Christensen resigns; CFO Robert Peterson named Interim CEO
Filed June 2, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
high
CEO Bret Christensen resigned effective June 8, 2026. The company stated the departure was not due to disagreement on operations or policies. He remains on the Board as Class III director through 2028 and receives options for 130,000 shares.
Item 5.02 verify on EDGAR → -
high
CFO Robert Peterson appointed Interim CEO effective June 8, 2026, while continuing as CFO. He will serve as both principal executive officer and principal financial officer simultaneously. Also appointed to Board as Class I director through 2029.
Item 5.02 verify on EDGAR → -
high
Marc Beer appointed Executive Chairman effective June 8, 2026 with $521,200 base salary plus up to 85% performance bonus. Receives options for 114,157 shares and 18-month change-in-control severance package including base plus target bonus and COBRA coverage.
Item 5.02 verify on EDGAR → -
low
Board expanded from seven to eight directors to accommodate Peterson's appointment. Company issued press release on May 28, 2026 announcing the management changes.
Item 5.02, Item 9.01 verify on EDGAR →
Summary
Biote Corp. announced a significant leadership restructuring with CEO Bret Christensen stepping down effective June 8, 2026. While the company emphasized the resignation was amicable and not due to operational disagreements, the departure creates uncertainty during a critical period.
CFO Robert Peterson will assume dual roles as both Interim CEO and CFO, an unusual arrangement that concentrates executive authority and may strain operational oversight. The appointment of Marc Beer as Executive Chairman with substantial compensation ($521,200 base plus 85% bonus potential) and generous change-in-control protections suggests the Board is preparing for potential strategic alternatives or M&A activity.
Beer's severance package—18 months of pay plus full equity vesting upon a change in control—is notably investor-friendly for an executive but signals the company may be positioning itself for a transaction. Retail investors should monitor whether Biote names a permanent CEO quickly or if the interim arrangement persists, which could indicate difficulty attracting leadership or ongoing strategic review. Watch for any announcements about strategic alternatives, acquisition interest, or operational performance under the new structure in upcoming quarterly results.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 27, 2026, the Board of Directors (the “Board”) of biote Corp. (the “Company”) accepted the resignation of Bret Christensen, the Company’s Chief Executive Officer, from his position as Chief Executive Officer of BioTE Medical, LLC (“BioTE”), effective as of June 8, 2026. Such resignation did not result from any disagreement with BioTE or the Company on any matter relating to BioTE’s or the Company’s operations, policies or practices.
CEO Bret Christensen resigned effective June 8, 2026. The company stated the resignation was not due to any disagreement on operations, policies, or practices. Under his separation agreement, Christensen will remain on the Board as a Class III director until the 2028 Annual Meeting and receive a stock option to purchase 130,000 shares.
Added in current filing · verify on EDGAR →
If Mr. Beer’s Services Agreement is terminated by the Company without cause or he resigns for certain good reason, in either case within 1 month prior to or 12 months following the effective date of a change in control of the Company, and subject to his execution of an effective release of claims against BioTE and the Company, BioTE will continue to pay Mr. Beer, for the 18 month period following such termination date, a monthly amount equal to the sum of 1/12th of his then-current base compensation plus 1/12th of his annual target bonus. BioTE will also pay, or reimburse, premiums for Mr. Beer and any eligible dependents under COBRA (or analogous state law) for up to 18 months following such termination without cause or resignation for good reason. In addition, the unvested portion of all time-based equity awards granted to Mr. Beer on or after the date of the Services Agreement will become fully vested and, if applicable, exercisable.
Marc Beer's services agreement includes change-in-control severance provisions: 18 months of base plus target bonus, 18 months of COBRA coverage, and full vesting of time-based equity awards if terminated without cause or he resigns for good reason within the change-in-control window.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
In connection with Mr. Peterson’s appointment to the Board, the Board increased its size to eight (8) directors.
The Board expanded from seven to eight directors to accommodate Robert Peterson's appointment as a director concurrent with his Interim CEO role.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 28, 2026, the Company issued a press release with respect to the management changes described in Item 5.02 of this Current Report on Form 8-K.
Biote issued a press release on May 28, 2026 announcing management changes that are detailed in Item 5.02 of this filing. The press release is furnished as Exhibit 99.1 and is not deemed filed for SEC purposes.
Event · Item 9.01 — Financial Statements and Exhibits
Biote Corp. filed an 8-K attaching a press release dated May 28, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press Release dated May 28, 2026.
The 8-K references an attached press release dated May 28, 2026 (Exhibit 99.1). The filing body itself contains no substantive disclosure about the press release content, making this a procedural filing to satisfy SEC requirements for public dissemination of the release.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify